Obesity pharmaceutical correction in metabolic syndrome patients
Very high prevalence of obesity and metabolic syndrome (MS) is well known. The need for early treatment start and more selective pharmaceutical treatment of MS has been noted in many publications. As pathogenetic therapy, numerous methods for body mass (BM) reduction have been proposed, due to well-...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2005-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/991 |
| _version_ | 1797882835654148096 |
|---|---|
| author | V. B. Mychka I. E. Chazova V. V. Gornostaev V. B. Sergienko |
| author_facet | V. B. Mychka I. E. Chazova V. V. Gornostaev V. B. Sergienko |
| author_sort | V. B. Mychka |
| collection | DOAJ |
| description | Very high prevalence of obesity and metabolic syndrome (MS) is well known. The need for early treatment start and more selective pharmaceutical treatment of MS has been noted in many publications. As pathogenetic therapy, numerous methods for body mass (BM) reduction have been proposed, due to well-known prevalent role of obesity in MS pathogenesis. Because of various reasons, many medications haven’t achieved wide acceptance in clinical settings. The article summarizes the experience in BM reduction with an effective drug – orlistat (Xenical®). Based on the authentic authors’ data, beneficial effects of orlistat on carbohydrate and lipid metabolism, 24-hour blood pressure profile, and cerebral perfusion are demonstrated. The authors prove that orlistat is highly recommended for cardiovascular complication risk reduction in MS patients. |
| first_indexed | 2024-04-10T03:40:52Z |
| format | Article |
| id | doaj.art-be1b2df7405c426b993f444a3b297916 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:40:52Z |
| publishDate | 2005-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-be1b2df7405c426b993f444a3b2979162023-03-13T07:23:11Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252005-08-01447984705Obesity pharmaceutical correction in metabolic syndrome patientsV. B. Mychka0I. E. Chazova1V. V. Gornostaev2V. B. Sergienko3Научно-исследовательский институт клинической кардиологии им. А.Л. Мясникова РКНПК Росздрава, МоскваНаучно-исследовательский институт клинической кардиологии им. А.Л. Мясникова РКНПК Росздрава, МоскваНаучно-исследовательский институт клинической кардиологии им. А.Л. Мясникова РКНПК Росздрава, МоскваНаучно-исследовательский институт клинической кардиологии им. А.Л. Мясникова РКНПК Росздрава, МоскваVery high prevalence of obesity and metabolic syndrome (MS) is well known. The need for early treatment start and more selective pharmaceutical treatment of MS has been noted in many publications. As pathogenetic therapy, numerous methods for body mass (BM) reduction have been proposed, due to well-known prevalent role of obesity in MS pathogenesis. Because of various reasons, many medications haven’t achieved wide acceptance in clinical settings. The article summarizes the experience in BM reduction with an effective drug – orlistat (Xenical®). Based on the authentic authors’ data, beneficial effects of orlistat on carbohydrate and lipid metabolism, 24-hour blood pressure profile, and cerebral perfusion are demonstrated. The authors prove that orlistat is highly recommended for cardiovascular complication risk reduction in MS patients.https://cardiovascular.elpub.ru/jour/article/view/991метаболический синдромартериальная гипертонияожирениемедикаментозное лечениеорлистат |
| spellingShingle | V. B. Mychka I. E. Chazova V. V. Gornostaev V. B. Sergienko Obesity pharmaceutical correction in metabolic syndrome patients Кардиоваскулярная терапия и профилактика метаболический синдром артериальная гипертония ожирение медикаментозное лечение орлистат |
| title | Obesity pharmaceutical correction in metabolic syndrome patients |
| title_full | Obesity pharmaceutical correction in metabolic syndrome patients |
| title_fullStr | Obesity pharmaceutical correction in metabolic syndrome patients |
| title_full_unstemmed | Obesity pharmaceutical correction in metabolic syndrome patients |
| title_short | Obesity pharmaceutical correction in metabolic syndrome patients |
| title_sort | obesity pharmaceutical correction in metabolic syndrome patients |
| topic | метаболический синдром артериальная гипертония ожирение медикаментозное лечение орлистат |
| url | https://cardiovascular.elpub.ru/jour/article/view/991 |
| work_keys_str_mv | AT vbmychka obesitypharmaceuticalcorrectioninmetabolicsyndromepatients AT iechazova obesitypharmaceuticalcorrectioninmetabolicsyndromepatients AT vvgornostaev obesitypharmaceuticalcorrectioninmetabolicsyndromepatients AT vbsergienko obesitypharmaceuticalcorrectioninmetabolicsyndromepatients |